1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dezhan Healthcare Co., Ltd. Class A

Dezhan Healthcare Co., Ltd. Class A

SSZSE:000813
3.03
CNY
+0.01
(+0.33%)
6.35BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.91
0.87
0.9
0.64
0.99
1.47
0.8
0.43
0.33
0.26
0.23
0.22
0.19
- -
Basic EPS, GAAP
0.05
0.03
0.39
0.3
0.36
0.42
0.15
0.13
-0.03
-0.02
0.04
-0.01
-0.16
- -
Free Cash Flow per Basic Share
0.14
0.09
0.02
0.08
0.12
0.14
0.67
0.32
-0.04
0.04
-0.01
-0.08
-0.11
- -
Dividend per Share
0.04
0.03
0.01
- -
- -
- -
- -
- -
0.21
- -
- -
- -
- -
- -
Book Value per Share
1.48
1.51
2.13
1.67
2.03
2.36
2.5
2.63
2.4
2.38
2.42
2.38
2.21
2.18
Tangible Book Value per Share
0.27
0.3
3.1
1.63
1.99
2.32
2.47
2.45
2.18
2.19
2.2
2.17
2.02
1.99
Basic Weighted Avg Shares
628
645
1,317
2,241
2,242
2,236
2,218
2,220
2,241
2,215
2,181
2,149
2,115
2,108
Sales/Revenue/Turnover
569
559
1,179
1,443
2,220
3,291
1,775
963
734
571
498
466
397
- -
Operating Margin (%)
25.95
24.2
53.8
54.44
41.93
31.44
20
25.09
10.26
-8.28
-6.12
-15.45
-43.73
- -
Depreciation Expense
46
56
19
21
25
45
52
69
85
95
84
84
92
- -
Net Income, GAAP
29
22
509
662
797
931
337
285
-58
-47
83
-20
-345
- -
Effective Tax Rate (%)
34.3
46.43
16.67
15.16
15.38
11.62
13.43
21.65
- -
- -
33.72
- -
- -
- -
Profit Margin (%)
5.15
3.84
43.18
45.85
35.9
28.28
18.98
29.55
-7.84
-8.22
16.73
-4.38
-87.05
- -
Working Capital
98
6
1,158
3,165
3,865
4,535
4,712
4,380
3,313
3,623
3,442
3,241
2,412
1,988
LT Debt
204
123
120
- -
5
5
5
11
7
7
5
14
127
123
Total Equity
1,308
1,352
1,495
3,752
4,545
5,281
5,612
5,953
5,470
5,284
5,241
5,165
4,573
4,498
Return on Invested Capital (%)
4.13
2.38
29.61
24.16
18.86
18.69
6.01
4.77
- -
- -
1.01
- -
- -
- -
Return on Capital (%)
-0.34
0.09
31.34
24.86
19.26
18.92
6.2
5.1
- -
- -
2.14
- -
- -
- -
Return on Common Equity (%)
3.08
2.06
39.92
25.22
19.21
18.94
6.19
4.94
-1.02
-0.88
1.58
-0.39
-7.05
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8
8
8
LT Borrowings
113
113
113
LT Finance Leases
13
12
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,097
2,097
2,097
Market Capitalization
8,053
7,382
6,354

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,568
2,172
2,121
Cash, Cash Equivalents & STI
1,816
1,416
1,348
Accounts Receivable, Net
234
254
274
Inventories
148
133
138
Total Current Liabilities
156
130
133
Payables & Accruals
- -
- -
- -
ST Debt
8
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.54%
-5.05%
-11.47%
Free Cash Flow
112.95%
7.84%
27.67%
Net Income, GAAP
103.93%
210.3%
1,592.15%
Sales/Revenue/Turnover
-4.74%
-16.01%
-14.94%
Total Cash Common Dividend
- -
- -
1,757.41%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
147
106
112
466
2025
89
77
- -
119
397
2026
89
54
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.01
- -
-0.01
-0.01
2025
-0.01
-0.01
- -
-0.14
-0.16
2026
-0.02
-0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wei Liu
Full Time Employees
1,195
Sector
Health technology
Industry
Pharmaceuticals: major
Address
First Shanghai Center Beijing XI China 100025
IPO Date
May 19, 1998
Website
dezhanhealthcare.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dezhan Healthcare Company Limited engages in the research, development, production and sale of pharmaceuticals, primarily cardiovascular and cerebrovascular drugs, anti-cancer medications and healthcare products in China. The company offers specific products including atorvastatin calcium tablets (Amlodipine), amlodipine atorvastatin calcium tablets (Neil), warfarin sodium tablets, trimetazidine hydrochloride capsules and tablets (Fengle), amiodarone tablets, famciclovir tablets (Vanle), azathioprine tablets, hydroxyurea tablets and colchicine tablets; its wholly-owned subsidiary Jialin Pharmaceutical contributes key manufacturing capabilities. Founded in 1980 as Tianshan Textile and listed on the Shenzhen Stock Exchange in 1998, the company underwent asset restructuring and name change from Jialin Pharmaceutical in 2016, with control shifting to the Xinjiang State-owned Assets Administration Commission in 2021, positioning it as the sole listed pharmaceutical entity in the Xinjiang state-owned assets system; it maintains headquarters in Beijing. Recent developments include a cooperation agreement with Baoshi Hua Medical Technology to construct Hainan Decheng International Hospital and an agreement to acquire an additional 18% stake in Shanghai Deyi Pharmaceutical Co., Ltd. from Hanyi Biotechnology Co., alongside completion of an equity buyback program in 2024 repurchasing 67.85 million shares for CNY 200.88 million. Operations focus on the domestic Chinese market through an integrated industrial chain, with national recognitions such as National Key Torch Program and National Science and Technology Progress awards.